These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 36758520)

  • 1. Biomarker-responsive engineered probiotic diagnoses, records, and ameliorates inflammatory bowel disease in mice.
    Zou ZP; Du Y; Fang TT; Zhou Y; Ye BC
    Cell Host Microbe; 2023 Feb; 31(2):199-212.e5. PubMed ID: 36758520
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dual engineered bacteria improve inflammatory bowel disease in mice.
    Wu YQ; Zou ZP; Zhou Y; Ye BC
    Appl Microbiol Biotechnol; 2024 May; 108(1):333. PubMed ID: 38739270
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Construction of a sustainable 3-hydroxybutyrate-producing probiotic Escherichia coli for treatment of colitis.
    Yan X; Liu XY; Zhang D; Zhang YD; Li ZH; Liu X; Wu F; Chen GQ
    Cell Mol Immunol; 2021 Oct; 18(10):2344-2357. PubMed ID: 34480146
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recombinant probiotic therapy in experimental colitis in mice.
    Gardlik R; Palffy R; Celec P
    Folia Biol (Praha); 2012; 58(6):238-45. PubMed ID: 23438849
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prebiotics-Controlled Disposable Engineered Bacteria for Intestinal Diseases.
    Fang TT; Zou ZP; Zhou Y; Ye BC
    ACS Synth Biol; 2022 Sep; 11(9):3004-3014. PubMed ID: 36037444
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bifidobacterium longum and VSL#3
    Chen X; Fu Y; Wang L; Qian W; Zheng F; Hou X
    Dev Comp Immunol; 2019 Mar; 92():77-86. PubMed ID: 30227219
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Effectiveness of Probiotics in the Treatment of Inflammatory Bowel Disease (IBD)-A Critical Review.
    Jakubczyk D; Leszczyńska K; Górska S
    Nutrients; 2020 Jul; 12(7):. PubMed ID: 32630805
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is there any place for alimentary probiotics, prebiotics or synbiotics, for patients with inflammatory bowel disease?
    Seksik P; Dray X; Sokol H; Marteau P
    Mol Nutr Food Res; 2008 Aug; 52(8):906-12. PubMed ID: 18384087
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genotoxicity of Escherichia coli Nissle 1917 strain cannot be dissociated from its probiotic activity.
    Olier M; Marcq I; Salvador-Cartier C; Secher T; Dobrindt U; Boury M; Bacquié V; Pénary M; Gaultier E; Nougayrède JP; Fioramonti J; Oswald E
    Gut Microbes; 2012; 3(6):501-9. PubMed ID: 22895085
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Probiotic Cocktail Alleviates Intestinal Inflammation Through Improving Gut Microbiota and Metabolites in Colitis Mice.
    Zhu Y; Xu Y; Wang X; Rao L; Yan X; Gao R; Shen T; Zhou Y; Kong C; Zhou L
    Front Cell Infect Microbiol; 2022; 12():886061. PubMed ID: 35782138
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Engineering bacterial thiosulfate and tetrathionate sensors for detecting gut inflammation.
    Daeffler KN; Galley JD; Sheth RU; Ortiz-Velez LC; Bibb CO; Shroyer NF; Britton RA; Tabor JJ
    Mol Syst Biol; 2017 Apr; 13(4):923. PubMed ID: 28373240
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emerging strategies for engineering Escherichia coli Nissle 1917-based therapeutics.
    Lynch JP; Goers L; Lesser CF
    Trends Pharmacol Sci; 2022 Sep; 43(9):772-786. PubMed ID: 35232591
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Presume Why Probiotics May Not Provide Protection in Inflammatory Bowel Disease through an Azoxymethane and Dextran Sodium Sulfate Murine Model.
    Hu ML; Lian WS; Wang FS; Yang CH; Huang WT; Yang JW; Chen IY; Yang MY
    Int J Mol Sci; 2022 Aug; 23(17):. PubMed ID: 36077084
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Probiotics: The scientific evidence in the context of inflammatory bowel disease.
    Celiberto LS; Bedani R; Rossi EA; Cavallini DC
    Crit Rev Food Sci Nutr; 2017 Jun; 57(9):1759-1768. PubMed ID: 25996176
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Probiotics in the management of inflammatory bowel disease: a systematic review of intervention studies in adult patients.
    Jonkers D; Penders J; Masclee A; Pierik M
    Drugs; 2012 Apr; 72(6):803-23. PubMed ID: 22512365
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Engineered probiotics.
    Ma J; Lyu Y; Liu X; Jia X; Cui F; Wu X; Deng S; Yue C
    Microb Cell Fact; 2022 Apr; 21(1):72. PubMed ID: 35477497
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rationale for probiotic treatment strategies in inflammatory bowel disease.
    Schultz M; Lindström AL
    Expert Rev Gastroenterol Hepatol; 2008 Jun; 2(3):337-55. PubMed ID: 19072384
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An engineered Escherichia coli Nissle 1917 increase the production of indole lactic acid in the gut.
    Dimopoulou C; Bongers M; Pedersen M; Bahl MI; Sommer MOA; Laursen MF; Licht TR
    FEMS Microbiol Lett; 2023 Jan; 370():. PubMed ID: 37028942
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Self-tunable engineered yeast probiotics for the treatment of inflammatory bowel disease.
    Scott BM; Gutiérrez-Vázquez C; Sanmarco LM; da Silva Pereira JA; Li Z; Plasencia A; Hewson P; Cox LM; O'Brien M; Chen SK; Moraes-Vieira PM; Chang BSW; Peisajovich SG; Quintana FJ
    Nat Med; 2021 Jul; 27(7):1212-1222. PubMed ID: 34183837
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Probiotic
    Zhao Z; Xu S; Zhang W; Wu D; Yang G
    Food Funct; 2022 Jun; 13(11):5914-5924. PubMed ID: 35583304
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.